Sheyda Abdullaeva

In our study, we showed the optimal cut-off value between high and low TIL levels in triple negative breast cancer. TIL >40% is significantly associated with better event-free survival. #TILs #TNBC #SABCS24

Anthropic pays $750,000+ a year for engineers who can build LLM architectures from scratch. This 2-hour Stanford lecture gives you the exact pipeline LLM engineers get paid $750K/year for. Data + architecture + scaling laws + post-training. Bookmark it & watch today. Then read article below.

ASCO this year has 5,000+ abstracts. But ~24 will actually change practice. Here is that map. Data-grid is the shortest path through ASCO 2026: 12 disease areas, 24 critical readouts, 5 plenaries, and 2 (confirmed) misses already on the board. Few things jump out immediately: ▪️Daraxonrasib gets the headline (13.2 vs 6.7 mo) ▫️Sarcoma gets a plenary as public science funds P3 that pharma would not. ▫️Lung cancer remains crowded: RET adjuvant, bispecific OS, post-osimertinib, next-gen EGFR. ▫️Breast cancer reminds us that not every big swing lands By next week, only a handful of these cells will become new standards of care. This is your cheat sheet to keep that score. - - - - - Source: @asco · @OncLive · @CancerNetwrk · via @Jori_health - - - - -

ESMO Breast 2026 — key trials at a glance • HER2+ trials • HR+/HER2− trials • TNBC / ADC / Immunotherapy trials Major studies, key results, and clinical take-home messages — all in one quick visual summary. #ESMOBreast2026 #BreastCancer #Oncology #MVOnco

I Cancelled Spotify. I cancelled Disney+. I cancelled Apple TV+. No more paying every month. Claude transformed my laptop into a free entertainment center. Here are 8 prompts to create this system:

10 websites that feel illegal to use. All 100% free. Bookmark this before it gets deleted. 👇

🚨 Stop using Claude like it’s ChatGPT — they’re completely different tools. Here’s how to set it up the right way in just 10 minutes 📸 (Save this for later 🔖)

PFS2 as a surrogate for OS in breast cancer? 🧠 🆕 ESMO Open 2026 systematic review of 18 RCTs (n = 9,617) 🎯 Question: Can PFS2 reliably predict OS in breast cancer? 📊 Primary analysis •r = 0.71 •R² = 0.51 → ~51% of OS variability explained by PFS2 ⚠️ Long-term OS validation: •r = 0.55 •R² = 0.30 → Signal weakens with maturity 🔬 Surrogacy improves only when: •PFS2 maturity ≥55% → R² = 0.86 •OS information fraction ≥75% → R² = 0.87 But not consistent in long-term validation. 📌 Interestingly: PFS1 showed slightly stronger association with OS •r = 0.77 •R² = 0.60 💡 Takeaway: PFS2 is context-dependent, not a robust universal surrogate. Endpoint maturity matters. Clinical setting matters. Be cautious before accepting PFS2 as a primary decision driver. #OncoTwitter #MedTwitter #BreastCancer #ClinicalTrials @OncoAlert @myESMO @ASCO @JCOPO_ASCO @stolaney1 @PTarantinoMD

PFS2 as a surrogate endpoint for OS in breast cancer randomized controlled clinical trials in @ESMO_Open. Context-dependent association, stronger association with higher PFS2 maturity and OS information fraction. esmoopen.com/article/S2059-…

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors in @ESMO_Open. Evidence-based consensus statements providing guidance on the safety of combining RT with EGFR, ALK, or BRAF/MEK inhibitors. esmoopen.com/article/S2059-…

⚠️ RT + Targeted Therapy = Hidden Toxicity Risk? New ESMO–ESTRO consensus on combining radiotherapy with: 🔹 EGFR inhibitors 🔹 ALK inhibitors 🔹 BRAF/MEK inhibitors 📄 Review in ESMO Open 2026 🟣 EGFR inhibitors • ↑ Dermatitis & mucositis risk • Thoracic RT + osimertinib → high pneumonitis risk • Major adaptation recommended in most high-dose settings 🔵 ALK inhibitors • Evidence limited • Most scenarios → major adaptation advised • CNS combinations need caution 🔴 BRAF/MEK inhibitors • Clear ↑ skin toxicity • High-dose skin RT → avoid combination • Vemurafenib + skin RT → do NOT combine @OncoAlert @myESMO @ASCO

• Pegfilgrastim timing matters • 24h → higher early WBC spike • 72h → ↓ bone pain • 72h → more controlled WBC curve • No loss of efficacy Maybe 72 hours is the sweet spot 👇 #MVOnco #Pegfilgrastim #GCSF #Oncology #SupportiveCare #DoseDense

The St Gallen Consensus @SG_BCC for early breast cancer still outperforms AI including ChatGPT and Deepseek. For now! link.springer.com/content/pdf/10… @curijoey

Enjoy!!! #v=onepage&q&f=false" target="_blank" rel="nofollow noopener">books.google.com.pe/books?id=ZVO0D…

Press release for #LIBRETTO432 is positive (primary end point of Event free survival)! Trending OS but immature right now. Selpercatinib in Adj settings (for 3yrs) status post surgery or radiation for Stage IB-IIIA NSCLC w/ RET fusion-positive disease. #lcsm #OncTwitter #MedX

@DrHBurstein @curijoey @DrKateDibble @IEOufficiale For endocrine therapy in premenopausal pts with HR+/HER2+ eBC, don’t miss our editorial in The Breast (with Meredith Regan and @AnnPartridgeMD) 👉 thebreastonline.com/article/S0960-… 13/

BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer - The Breast thebreastonline.com/article/S0960-…

41y on Tamoxifen. Amenorrhea ×2 yrs. FSH 88. E2 18. Can we switch to Letrozole? 🤔 • Is FSH reliable? • Does E2 decide? • Chemo suppression vs true menopause? • Can we start OFS + AI on Day 1? Endocrine nuances simplified 👇 #BreastCancer #EndocrineRx #Oncology #MVOnco

New data from TBCRC 048 published in @JCO_ASCO. Pretty definitive answer on the activity of PARPi for patients with MBC and gPALB2 mutations: ORR 75%, CBR 83%, mPFS 9.4 months. @TheTBCRC #tbl3" target="_blank" rel="nofollow noopener">ascopubs.org/doi/10.1200/JC…

PATINA is now out in @nejm. Among pts with HR+/HER2+ MBC progression-free after chemo induction, adding palbociclib to 1L ET+HER2-blockade maintenance prolonged PFS from 29 mo to an astonishing 44 months (HR 0.75, p=0.02). Congrats @Otto_DFCI & coauthors! nejm.org/doi/full/10.10…

👉 FREE Tools for Your Research ➡️ This 7-step academic research workflow highlights free and freemium digital tools that help researchers move smoothly from literature discovery to reference management, without heavy costs or complexity. ➡️ 1. Literature Search 🔹 Completely Free: Semantic Scholar, Smart Search, Insight. dev 🔹 Freemium: Consensus, Scispace, Evidence Hunt, R Discovery, Scinapse ➡️ 2. Literature Mapping 🔹 Research Rabbit 🔹 Inciteful 🔹 Open Knowledge Maps 🔹 VOSviewer ➡️ 3. Reading and Note Taking 🔹 Lumina Chat 🔹 PDF Gear 🔹 GLASP 🔹 Save Day ➡️ 4. Data Analysis 🔹 JASP 🔹 Simple ML for Sheets 🔹 R 🔹 Code Interpreter in BingAI ➡️ 5. Images and Flow Charts 🔹 Draw. io 🔹 Inkscape 🔹 Meta AI 🔹 Bing Image Creator ➡️ 6. Editing / Proofreading 🔹 Edit GPT 🔹 Hemingway Editor 🔹 Paraphraser 🔹 KamousAI ➡️ 7. Reference Manager 🔹 Zotero 🔹 Mendeley 🔹 JabRef Used together, these tools create a practical end-to-end research system that saves time, improves clarity, and supports high-quality academic output especially for students and independent researchers. ❤️ Like 🔁 Retweet 🔖 Bookmark Follow @sonalshukla3377 for more such posts